BridgeBio Pharma Inc (BBIO) - Total Liabilities
Based on the latest financial reports, BridgeBio Pharma Inc (BBIO) has total liabilities worth $2.92 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore BBIO net asset momentum to track the company's year-over-year net asset growth rate.
BridgeBio Pharma Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how BridgeBio Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. See BridgeBio Pharma Inc (BBIO) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
BridgeBio Pharma Inc Competitors by Total Liabilities
The table below lists competitors of BridgeBio Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LTIMindtree Limited
NSE:LTIM
|
India | Rs105.22 Billion |
|
Cemex SAB de CV ADR
F:CEXA
|
Germany | €14.66 Billion |
|
Pinnacle Financial Partners, Inc.
NASDAQ:PNFP
|
USA | $49.11 Billion |
|
Masco Corporation
NYSE:MAS
|
USA | $5.21 Billion |
|
Unibail-Rodamco-Westfield
PA:URW
|
France | €31.98 Billion |
|
SANDS CHINA ADR/1 O.N.
F:599
|
Germany | €9.17 Billion |
|
Xian LONGi Silicon Materials Corp
SHG:601012
|
China | CN¥96.59 Billion |
|
Henkel AG & Co. KGaA vz. (Pref Shares)
XETRA:HEN3
|
Germany | €12.67 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down BridgeBio Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BBIO market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.93 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BridgeBio Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BridgeBio Pharma Inc (2017–2024)
The table below shows the annual total liabilities of BridgeBio Pharma Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.38 Billion | +25.84% |
| 2023-12-31 | $1.89 Billion | +1.12% |
| 2022-12-31 | $1.87 Billion | -0.55% |
| 2021-12-31 | $1.88 Billion | +215.32% |
| 2020-12-31 | $595.70 Million | +282.59% |
| 2019-12-31 | $155.70 Million | -72.51% |
| 2018-12-31 | $566.44 Million | +270.88% |
| 2017-12-31 | $152.73 Million | -- |
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM);… Read more